Adalimumab originator versus adalimumab biosimilars in inflammatory bowel disease in Australia-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Adalimumab originator versus adalimumab biosimilars in inflammatory bowel disease in Australia

Published:2023-04-19 Issue:8 Volume:23 Page:819-825
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Anderson Emilia¹,Waller Karen¹^ORCID,Tamilarasan Aravind Gokul¹²^ORCID,Lin Huiyu¹^ORCID,Paramsothy Sudarshan¹²³⁴^ORCID,Leong Rupert W¹²³⁴^ORCID

Affiliation:

1. Department of Gastroenterology and Hepatology, Concord Repatriation General Hospital, Sydney, NSW, Australia

2. Faculty of Medicine and Health, Concord Clinical School, University of Sydney, Sydney, NSW, Australia

3. Department of Gastroenterology, Macquarie University Hospital, Sydney, NSW, Australia

4. Faculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW, Australia

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14712598.2023.2203812

Reference26 articles.

2. Therapeutic Goods Administration, Australian Government Department of Health. Biosimilar medicines regulation. [Internet] 2018 [cited 2021 Aug 16]; Available from: https://www.tga.gov.au/publication/biosimilar-medicines-regulation

3. Adalimumab Biosimilars in Europe: An Overview of the Clinical Evidence

5. The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP